President
CurrentAs President, responsible for the commercial operations, business development and strategy for Virios Therapeutics, LLC, a Biotech company developing novel viral mediated treatments for fibromyalgia, irritable bowel syndrome, chronic fatigue syndrome and other related conditions. Our lead compound, IMC-1 which successfully completed a Phase 2a trial in fibromyalgia received Fast Track designation from the FDA for the treatment of FM . This data was made public during an oral presentation at the American College of Rheumatology annual meeting. IMC is driven to improve patient outcomes by finally answering an underlying cause of fibromyalgia and related conditions. The company went public December 2020.